| 摘要: |
| ［摘要］ 目的 探讨细胞周期依赖性蛋白12（CDK12）突变型前列腺癌的临床病理特征、突变类型及治疗方式。方法 报告10例CDK12突变型前列腺癌患者的临床病理特征、基因检测结果和随访资料，复习相关文献并进行讨论。结果 10例患者平均确诊年龄为（66.60±6.80）岁，平均血清前列腺特异性抗原为652.19 ng/ml，并且穿刺Gleason评分均≥8分，8例患者确诊时已出现远处转移。此外，6例患者的CDK12突变发生在去势抵抗阶段。结论 CDK12突变型前列腺癌恶性程度较高且易进展至去势抵抗，该部分患者可能会从铂类化疗、聚ADP核糖聚合酶（PARP）抑制剂或免疫治疗中获益。 |
| 关键词: 前列腺癌 细胞周期依赖性蛋白12突变 临床病理特征 治疗 预后 |
| DOI：10.3969/j.issn.1674-3806.2021.07.06 |
| 分类号:R 737.25 |
| 基金项目:吴阶平医学基金会临床科研专项资助基金项目（编号：320.6750.2020-14-11） |
|
| Analysis of the clinicopathological characteristics of CDK12-mutant prostate cancer in a single center |
|
FAN Jun-jie, JIANG Fan, HE Da-lin, et al.
|
|
Department of Urology, the First Affiliated Hospital of Xi′an Jiaotong University, Shanxi 710061, China
|
| Abstract: |
| ［Abstract］ Objective To investigate the clinicopathological characteristics, types of mutation and treatment methods of cell cycle-dependent kinase 12(CDK12)-mutant prostate cancer(PCa). Methods The clinicopathological characteristics, gene mutation results and follow-up data of 10 patients with CDK12-mutant PCa were reported, and the related literature was reviewed and discussed. Results The mean age of the 10 patients with a definite diagnosis was (66.60±6.80)years, and their mean serum prostate-specific antigen was 652.19 ng/ml, and their Gleason scores of puncture were more than or equal to 8 points. Of the 10 patients, eight had distant metastasis at the time of diagnosis. In addition, CDK 12 mutation occurred in castration-resistant stage in 6 patients. Conclusion Patients with CDK12-mutant PCa, which has a high degree of malignancy and is prone to castration-resistant stage, may benefit from platinum-based chemotherapy, poly ADP-ribose polymerase(PARP) inhibitors or immunotherapy. |
| Key words: Prostate cancer(PCa) Cell cycle-dependent kinase 12(CDK12) mutation Clinicopathological characteristics Treatment Prognosis |
